HUP0303199A2 - Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására - Google Patents
Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállításáraInfo
- Publication number
- HUP0303199A2 HUP0303199A2 HU0303199A HUP0303199A HUP0303199A2 HU P0303199 A2 HUP0303199 A2 HU P0303199A2 HU 0303199 A HU0303199 A HU 0303199A HU P0303199 A HUP0303199 A HU P0303199A HU P0303199 A2 HUP0303199 A2 HU P0303199A2
- Authority
- HU
- Hungary
- Prior art keywords
- identification
- cell epitopes
- immunogenicity
- reeduced
- new
- Prior art date
Links
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A találmány tárgya egy új megközelítési mód élő szervezetbenimmunválaszt kiváltó T-sejt-epitópok azonosítására. Ennek az újeljárásnak az alkalmazásával olyan biológiai vegyületek állíthatókelő, amelyeknek nincs vagy csökkentett az immunogenitása, amikortalálkoznak egy adott faj immunrendszerével, összehasonlítva areleváns nem módosított entitással. Ily módon a találmány tárgyátképezik új biológiai molekulák, különösen fehérjék és ellenanyagok is,amelyek a találmány szerinti eljárással állíthatók elő. Ó
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01103954 | 2001-02-19 | ||
EP01105777 | 2001-03-08 | ||
EP01106536 | 2001-03-15 | ||
EP01106538 | 2001-03-15 | ||
EP01107012 | 2001-03-20 | ||
EP01106899 | 2001-03-20 | ||
EP01107568 | 2001-03-27 | ||
EP01110220 | 2001-04-25 | ||
EP01113228 | 2001-05-30 | ||
EP01124965 | 2001-10-19 | ||
EP01126859 | 2001-11-12 | ||
PCT/EP2002/001688 WO2002069232A2 (en) | 2001-02-19 | 2002-02-18 | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0303199A2 true HUP0303199A2 (hu) | 2003-12-29 |
Family
ID=27581535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303199A HUP0303199A2 (hu) | 2001-02-19 | 2002-02-18 | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására |
Country Status (14)
Country | Link |
---|---|
US (1) | US7430476B2 (hu) |
EP (2) | EP1998266A3 (hu) |
JP (1) | JP4279554B2 (hu) |
KR (1) | KR100899970B1 (hu) |
CN (1) | CN100404673C (hu) |
AT (1) | ATE400030T1 (hu) |
AU (1) | AU2002256624B2 (hu) |
CA (1) | CA2438652A1 (hu) |
ES (1) | ES2309167T3 (hu) |
HU (1) | HUP0303199A2 (hu) |
MX (1) | MXPA03007316A (hu) |
PL (1) | PL362414A1 (hu) |
WO (1) | WO2002069232A2 (hu) |
ZA (1) | ZA200307324B (hu) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
RU2229305C2 (ru) * | 1998-04-15 | 2004-05-27 | Лексиген Фармасьютикэлс Корпорейшн | Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза |
CA2372794A1 (en) * | 1999-05-14 | 2000-11-23 | Mcgill University | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
PL202058B1 (pl) * | 1999-08-09 | 2009-05-29 | Merck Patent Gmbh | Wielofunkcyjne białko fuzyjne cytokin i przeciwciała |
HUP0300868A3 (en) * | 2000-06-29 | 2005-11-28 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
DK200101090A (da) | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
PL369739A1 (en) * | 2001-11-12 | 2005-05-02 | Merck Patent Gmbh | Modified anti-tnf alpha antibody |
MXPA04004970A (es) * | 2001-11-29 | 2004-08-11 | Merck Patent Gmbh | Epitopos de linfocitos t en carboxipeptidasa g2. |
EP2354791A1 (en) | 2001-12-04 | 2011-08-10 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
DK1530637T3 (da) * | 2002-02-26 | 2010-05-31 | Genencor Int | Carlsberg-subtilisin-proteiner med nedsat immunogenitet |
WO2003103715A1 (en) * | 2002-06-11 | 2003-12-18 | Merck Patent Gmbh | Modified byrodin 1 with reduced immunogenicity |
DE60322225D1 (en) * | 2002-08-09 | 2008-08-28 | Merck Patent Gmbh | T-zellen-epitope in erythropoietin |
WO2004039832A2 (en) * | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
PL217296B1 (pl) * | 2002-11-15 | 2014-07-31 | Genmab As | Wyizolowane ludzkie przeciwciało monoklonalne, wytwarzająca je hybrydoma, kodujący to przeciwciało wektor ekspresyjny i zawierająca je kompozycja farmaceutyczna, immunokoniugat, bispecyficzna lub multispecyficzna cząsteczka obejmująca kwasy nukleinowe kodujące ciężki i lekki łańcuch transfektoma, ich zastosowania, zwłaszcza w medycynie, obejmująca te kwasy ex vivo eukariotyczna lub prokariotyczna komórka gospodarza oraz nie będące człowiekiem zwierzę transgeniczne lub roślina, sposób in vitro hamowania wzrostu i/lub proliferacji komórek wyrażających CD25 lub eliminowania komórek wyrażających CD25, sposób wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25, zestaw diagnostyczny do wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25 |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2004108158A1 (en) * | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
EP1636264A2 (en) * | 2003-06-24 | 2006-03-22 | MERCK PATENT GmbH | Tumour necrosis factor receptor molecules with reduced immunogenicity |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
ES2358427T3 (es) | 2003-10-16 | 2011-05-10 | Micromet Ag | Elementos de unión a cd-3 desinmunizados multiespecíficos. |
EP1694706B1 (en) * | 2003-11-01 | 2012-04-04 | Merck Patent GmbH | Modified anti-cd52 antibody |
AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
WO2005062042A1 (en) * | 2003-12-18 | 2005-07-07 | Genencor International, Inc. | Beta-lactamase cd4+ t-cell epitopes |
PT1699822E (pt) | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
AU2004309063B2 (en) * | 2003-12-31 | 2010-10-28 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
PT1706428E (pt) * | 2004-01-22 | 2009-12-29 | Merck Patent Gmbh | Anticorpos anticancerígenos com fixação de complemento reduzida |
EP1737961B1 (en) | 2004-03-19 | 2013-05-08 | Merck Patent GmbH | Modified bouganin proteins, cytotoxins and methods and uses thereof |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
US20060073563A1 (en) * | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
AU2012209017B2 (en) * | 2005-02-03 | 2014-06-26 | Antitope Limited | Human antibodies and proteins |
ES2417133T3 (es) * | 2005-02-03 | 2013-08-06 | Antitope Limited | Anticuerpos y proteínas humanas |
DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
PL1966238T3 (pl) * | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
EP1984403A2 (en) | 2006-01-12 | 2008-10-29 | Alexion Pharmaceuticals, Inc. | Antibodies to ox-2/cd200 and uses thereof |
WO2008105826A2 (en) * | 2006-09-05 | 2008-09-04 | Biosynexus Incorporated | Compositions compromising lysostaphin variants and methods of using the same |
AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
US8562986B2 (en) * | 2007-07-17 | 2013-10-22 | Merck Patent Gmbh | Engineered anti-alpha V-integrin hybrid antibodies |
CN101918532B (zh) | 2007-08-22 | 2016-03-30 | 普罗柏欧贞股份公司 | 用于体外测试免疫原性和免疫功能的培养***和方法 |
PT2808343T (pt) | 2007-12-26 | 2019-09-04 | Xencor Inc | Variantes fc com ligação alterada a fcrn |
WO2009110944A1 (en) | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
JP5683455B2 (ja) | 2008-05-29 | 2015-03-11 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | 親和性を改変した単純ヘルペスウイルス(hsv)、その使用および調製法 |
AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
WO2010121766A1 (en) * | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
WO2010124259A1 (en) * | 2009-04-24 | 2010-10-28 | Centre Hospitalier Universitaire Sainte-Justine | Allosteramers for tnf receptors and uses thereof |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8932588B2 (en) | 2009-11-05 | 2015-01-13 | Teva Pharmaceuticals Australia Pty. Ltd. | Treatment of cancer involving mutated KRAS or BRAF genes |
SG182408A1 (en) | 2010-01-11 | 2012-08-30 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
TWI796132B (zh) | 2010-02-24 | 2023-03-11 | 美商免疫遺傳股份有限公司 | 葉酸受體1抗體類和免疫共軛物類及彼等之用途 |
CN102906108B (zh) | 2010-03-04 | 2016-01-20 | 菲尼克斯公司 | 用于无变性制备可溶性重组干扰素蛋白的方法 |
PL2552949T3 (pl) | 2010-04-01 | 2017-01-31 | Pfenex Inc. | Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas |
CN105963694B (zh) | 2010-04-30 | 2019-11-05 | 阿雷克森制药公司 | 抗-c5a抗体和使用所述抗体的方法 |
SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
JP2012041316A (ja) * | 2010-08-23 | 2012-03-01 | Akita Univ | 新規ペプチド並びに分子シャペロン誘導剤及び抗がん剤 |
AR085141A1 (es) | 2011-02-03 | 2013-09-11 | Alexion Pharma Inc | Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos |
MX352025B (es) | 2011-02-11 | 2017-11-07 | Merck Patent Gmbh | Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata. |
KR20140012127A (ko) * | 2011-03-14 | 2014-01-29 | 세로두스 에이에스에이 | 인터류킨-1 수용체의 길항제 |
US8709432B2 (en) | 2011-04-01 | 2014-04-29 | Immunogen, Inc. | Methods for increasing efficacy of FOLR1 cancer therapy |
US9073965B2 (en) | 2011-04-12 | 2015-07-07 | Temple University—Of the Commonwealth System of Higher Education | Adiponectin receptor agonists and methods of use |
EP2793944A4 (en) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US20130216530A1 (en) * | 2012-02-02 | 2013-08-22 | Exagen Diagnostics, Inc. | Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants |
ME03799B (me) | 2012-08-31 | 2021-04-20 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
TW202206465A (zh) | 2012-11-14 | 2022-02-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
LT3038650T (lt) | 2013-08-30 | 2021-09-10 | Immunogen, Inc. | Antikūnai ir foliatų receptoriaus 1 nustatymo testai |
WO2015074048A1 (en) * | 2013-11-18 | 2015-05-21 | Siscapa Assay Technologies, Inc. | Measurement of gamma-carboxylation of proteins |
WO2015143558A1 (en) | 2014-03-27 | 2015-10-01 | British Columbia Cancer Agency Branch | T-cell epitope identification |
US10358636B2 (en) | 2014-05-14 | 2019-07-23 | Stealth Biologics, Llc | Deimmunized lysostaphin and methods of use |
US11173205B2 (en) | 2014-11-05 | 2021-11-16 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
US20180247011A1 (en) * | 2015-09-01 | 2018-08-30 | The Administrators Of The Tulane Educational Fund | A method for cd4+ t-cell epitope prediction using antigen structure |
KR20180053319A (ko) | 2015-09-17 | 2018-05-21 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
US10913772B2 (en) * | 2016-03-09 | 2021-02-09 | Kine Sciences Co., Ltd. | Peptide for preventing or treating inflammatory diseases and use thereof |
KR101897122B1 (ko) * | 2016-03-09 | 2018-09-10 | 주식회사 바이오펩 | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 |
EP3523467A4 (en) * | 2016-10-04 | 2021-10-06 | The Council of the Queensland Institute of Medical Research | PEPTIDE LIBRARIES AND METHODS OF USE |
KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
GB201618432D0 (en) | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
US11339221B2 (en) | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
CN109206482B (zh) * | 2018-09-30 | 2021-12-10 | 福建蓝昊生物科技有限公司 | 一种抑制消化道炎症的海藻源短肽及其应用 |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
EP3757127A1 (en) * | 2019-06-28 | 2020-12-30 | Institute for Research in Biomedicine | Deimmunized antibodies binding to alpha-4 integrin and uses thereof |
CN110694056B (zh) * | 2019-10-25 | 2023-05-05 | 四川农业大学 | 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗 |
MX2022013175A (es) * | 2020-04-29 | 2022-11-30 | Onegene Biotechnology Inc | Conjugado de proteinas novedoso, y uso del mismo para prevenir o tratar esteatohepatitis no alcoholica, obesidad y diabetes. |
CN112457399B (zh) * | 2020-12-19 | 2023-09-01 | 上海佰君生物科技有限公司 | 一种人免疫球蛋白g的提纯方法 |
CN112480245B (zh) * | 2020-12-19 | 2023-08-18 | 上海佰君生物科技有限公司 | 一种疏水性环状肽配基纯化人免疫球蛋白g的应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972682A (en) | 1984-05-29 | 1999-10-26 | Genencor International, Inc. | Enzymatically active modified subtilisins |
US5763257A (en) | 1984-05-29 | 1998-06-09 | Genencor International, Inc. | Modified subtilisins having amino acid alterations |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
US4914031A (en) | 1987-04-10 | 1990-04-03 | Amgen, Inc. | Subtilisin analogs |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SG46699A1 (en) | 1989-01-31 | 1998-02-20 | Jeffrey S Rubin | DNA encoding a growth factor specific for epithelial cells |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JPH03505976A (ja) | 1989-05-17 | 1991-12-26 | アムジエン・インコーポレーテツド | 多重突然変異スブチリシン |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5945397A (en) | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
US5986070A (en) | 1990-04-06 | 1999-11-16 | Amgen Inc. | Production of biologically active NGF proteins |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
BR9407035A (pt) | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5618714A (en) | 1993-12-15 | 1997-04-08 | Eli Lilly And Company | Methods for producing protein C |
ES2236706T3 (es) | 1994-03-23 | 2005-07-16 | Alexion Pharmaceuticals, Inc. | Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal. |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6008328A (en) | 1994-10-13 | 1999-12-28 | Amgen Inc. | Method for purifying keratinocyte growth factors |
US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5869330A (en) | 1995-06-05 | 1999-02-09 | Whitehead Institute For Biomedical Research | DNA encoding a novel serum protein produced exclusively in adipocytes |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
IL130396A (en) | 1996-12-20 | 2011-09-27 | Amgen Inc | OB fusion protein, nucleic acid sequence, vector, cell, process for protein production and pharmaceutical preparation |
US5741772A (en) | 1997-02-03 | 1998-04-21 | Amgen Inc. | Neurotrophic factor NNT-1 |
CA2288143C (en) | 1997-04-28 | 2012-08-21 | Eli Lilly And Company | Activated protein c formulations |
EP0983303B1 (en) * | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
AU2346900A (en) * | 1998-11-30 | 2000-06-19 | Eli Lilly And Company | Erythropoietic compounds |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
CA2356401A1 (en) | 1999-01-07 | 2000-07-13 | Lexigen Pharmaceuticals, Corp. | Expression and export of anti-obesity proteins as fc fusion proteins |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
-
2002
- 2002-02-18 HU HU0303199A patent/HUP0303199A2/hu unknown
- 2002-02-18 AT AT02726112T patent/ATE400030T1/de not_active IP Right Cessation
- 2002-02-18 PL PL02362414A patent/PL362414A1/xx not_active Application Discontinuation
- 2002-02-18 MX MXPA03007316A patent/MXPA03007316A/es active IP Right Grant
- 2002-02-18 CA CA002438652A patent/CA2438652A1/en not_active Abandoned
- 2002-02-18 US US10/468,496 patent/US7430476B2/en not_active Expired - Lifetime
- 2002-02-18 CN CNB028051572A patent/CN100404673C/zh not_active Expired - Fee Related
- 2002-02-18 AU AU2002256624A patent/AU2002256624B2/en not_active Expired
- 2002-02-18 EP EP08011838A patent/EP1998266A3/en not_active Withdrawn
- 2002-02-18 WO PCT/EP2002/001688 patent/WO2002069232A2/en active IP Right Grant
- 2002-02-18 JP JP2002568279A patent/JP4279554B2/ja not_active Expired - Lifetime
- 2002-02-18 KR KR1020037010860A patent/KR100899970B1/ko not_active IP Right Cessation
- 2002-02-18 EP EP02726112A patent/EP1366455B1/en not_active Expired - Lifetime
- 2002-02-18 ES ES02726112T patent/ES2309167T3/es not_active Expired - Lifetime
-
2003
- 2003-09-18 ZA ZA2003/07324A patent/ZA200307324B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL362414A1 (en) | 2004-11-02 |
KR20030075201A (ko) | 2003-09-22 |
ES2309167T3 (es) | 2008-12-16 |
WO2002069232A2 (en) | 2002-09-06 |
WO2002069232A3 (en) | 2003-02-13 |
US7430476B2 (en) | 2008-09-30 |
AU2002256624B8 (en) | 2002-09-12 |
MXPA03007316A (es) | 2003-12-04 |
JP2004523754A (ja) | 2004-08-05 |
US20040180386A1 (en) | 2004-09-16 |
AU2002256624B2 (en) | 2007-12-06 |
CA2438652A1 (en) | 2002-09-06 |
ZA200307324B (en) | 2005-02-23 |
CN100404673C (zh) | 2008-07-23 |
EP1366455A2 (en) | 2003-12-03 |
EP1366455B1 (en) | 2008-07-02 |
EP1998266A2 (en) | 2008-12-03 |
KR100899970B1 (ko) | 2009-05-28 |
ATE400030T1 (de) | 2008-07-15 |
EP1998266A3 (en) | 2009-02-11 |
CN1493052A (zh) | 2004-04-28 |
JP4279554B2 (ja) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303199A2 (hu) | Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására | |
WO2004063963A3 (en) | Novel proteins with altered immunogenicity | |
UA93855C2 (ru) | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе | |
IN2015KN00290A (hu) | ||
ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
HUP0402048A2 (hu) | Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására | |
MXPA01011047A (es) | Secuencias genomicas de neisseria y metodos para su uso. | |
DK1679319T3 (da) | Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD) | |
EP2388271A3 (en) | Human Antibodies and Proteins | |
WO2003086308A3 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
WO2003070187A3 (en) | Fusion proteins of mycobacterium tuberculosis | |
WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
WO2003016464A3 (en) | Cancer specific oligosaccharide sequences and use thereof | |
CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
WO2020014097A8 (en) | Reagents and methods for treating cancer and autoimmune disease | |
WO2003016915A8 (en) | Tumor specific oligosaccharide sequences and use thereof | |
ATE372350T1 (de) | Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften | |
EP1297147B8 (en) | Compositions for the diagnosis and treatment of herpes simplex virus infection | |
WO2005026192A3 (en) | Hpv cd8+ t-cell epitopes | |
WO2002077012A3 (en) | Human papilloma virus immunoreative peptides | |
ATE345354T1 (de) | Methode zur identifizierung von helicobacter antigenen | |
YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
NO20020615L (no) | Vaksine | |
WO2005027847A3 (en) | Antibodies for use against sars | |
ATE366583T1 (de) | Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |